415 related articles for article (PubMed ID: 34103404)
1. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
Urban S; Neumann-Haefelin C; Lampertico P
Gut; 2021 Sep; 70(9):1782-1794. PubMed ID: 34103404
[TBL] [Abstract][Full Text] [Related]
2. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.
Suárez-Amarán L; Usai C; Di Scala M; Godoy C; Ni Y; Hommel M; Palomo L; Segura V; Olagüe C; Vales A; Ruiz-Ripa A; Buti M; Salido E; Prieto J; Urban S; Rodríguez-Frias F; Aldabe R; González-Aseguinolaza G
J Hepatol; 2017 Oct; 67(4):669-679. PubMed ID: 28527664
[TBL] [Abstract][Full Text] [Related]
3. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
4. Interplay between Hepatitis D Virus and the Interferon Response.
Zhang Z; Urban S
Viruses; 2020 Nov; 12(11):. PubMed ID: 33233762
[TBL] [Abstract][Full Text] [Related]
5. Innate immune recognition and modulation in hepatitis D virus infection.
Jung S; Altstetter SM; Protzer U
World J Gastroenterol; 2020 Jun; 26(21):2781-2791. PubMed ID: 32550754
[TBL] [Abstract][Full Text] [Related]
6. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies.
Zhang Z; Urban S
J Hepatol; 2021 Mar; 74(3):686-699. PubMed ID: 33276031
[TBL] [Abstract][Full Text] [Related]
7. Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection.
Oberhardt V; Hofmann M; Thimme R; Neumann-Haefelin C
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215790
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
9. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
10. Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8
Karimzadeh H; Kiraithe MM; Kosinska AD; Glaser M; Fiedler M; Oberhardt V; Salimi Alizei E; Hofmann M; Mok JY; Nguyen M; van Esch WJE; Budeus B; Grabowski J; Homs M; Olivero A; Keyvani H; Rodríguez-Frías F; Tabernero D; Buti M; Heinold A; Alavian SM; Bauer T; Schulze Zur Wiesch J; Raziorrouh B; Hoffmann D; Smedile A; Rizzetto M; Wedemeyer H; Timm J; Antes I; Neumann-Haefelin C; Protzer U; Roggendorf M
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669837
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis D Virus-Specific CD8
Kefalakes H; Koh C; Sidney J; Amanakis G; Sette A; Heller T; Rehermann B
Gastroenterology; 2019 May; 156(6):1805-1819.e9. PubMed ID: 30664876
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.
Giersch K; Allweiss L; Volz T; Helbig M; Bierwolf J; Lohse AW; Pollok JM; Petersen J; Dandri M; Lütgehetmann M
J Hepatol; 2015 Aug; 63(2):346-53. PubMed ID: 25795587
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
15. Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A; Heidrich B; Ernst S; Calle Serrano B; Caruntu FA; Curescu MG; Yalcin K; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Bremer B; Stift J; Grabowski J; Kirschner J; Port K; Cornberg M; Falk CS; Dienes HP; Hardtke S; Manns MP; Yurdaydin C; Wedemeyer H;
PLoS One; 2014; 9(7):e101002. PubMed ID: 25072849
[TBL] [Abstract][Full Text] [Related]
16. An update on HDV: virology, pathogenesis and treatment.
Alvarado-Mora MV; Locarnini S; Rizzetto M; Pinho JR
Antivir Ther; 2013; 18(3 Pt B):541-8. PubMed ID: 23792471
[TBL] [Abstract][Full Text] [Related]
17. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
18. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.
Wang W; Lempp FA; Schlund F; Walter L; Decker CC; Zhang Z; Ni Y; Urban S
J Hepatol; 2021 Aug; 75(2):311-323. PubMed ID: 33845061
[TBL] [Abstract][Full Text] [Related]
19. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
20. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
